More recently, they have emerged as effective treatments for obesity, slowing digestion, increasing feelings of fullness and reducing hunger
Triple-Hormone-Receptor Agonist Retatrutide for Obesity Phase 2, NEJM , 2023 ClinicalTrials.gov TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045), TRIUMPH-4 (NCT05931367) FDA Wegovy prescribing information, 2025 FDA Zepbound (tirzepatide) prescribing information, 2024 Medical disclaimer: This article is for informational purposes only
Moreover, a recent study conducted using data of over 300 patients in 10 years, linked the up-regulation of CT2 with poor survival of gut cancer patients (Zhao et al., 2018)
Liraglutide Injection (Weight Management) Current Version May 13, 2024 Written By Jake Peter Fact-checked By Dr
Rajguru ensures that every individual understands their treatment plan and feels confident about moving forward